Being the most impacful journal I expect that NEJM would be the ideal place to publish our Landmark Trial Results for the orphan indication of Glioblastoma.
When we submitted something to the NEJM we also followed their guidelines. Anyone can submit anything anywhere. What matters is acceptance. Needless to say say what happened to our submission ;). Seriously though, it’s obvious they were going to aim high. Why wouldn’t they or anyone else? Does it explain the silence? Yes. Does it predict acceptance? No.
Market Data 
Markets 
AI
